Replies to post #210827 on Biotech Values

[NY1972]

Enrolling MRD+ patients in relapsed AML, CLL, MM.... must be the top priority for CMO now. Additional CMR will validate TTI621's role in IO.

J&J also has JNJ-63709178, a potent humanized CD123 x CD3 in P1 AML. They were looking for a IgG1 CD47 mAb that provides a therapeutic window with limited toxicity.